BMPR2抗体

+ +

•  

   

     Red: Control Antigen (100ng); Purple: Antigen (10ng); Green: Antigen (50ng); Blue: Antigen (100ng);    

  
  

•  

   

     Western blot analysis using BMPR2 mouse mAb against Hela (1), A431 (2), NIH/3T3 (3), Cos7 (4) and PC-12 (5) cell lysate.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human breast cancer tissues (left) and tonsil tissues (right) using BMPR2 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human kidney cancer tissues (left) and stomach cancer tissues (right) using BMPR2 mouse mAb with DAB staining.    

  
  

BMPR2 (bone morphogenetic protein receptor type 2) is a transmembrane serine/threonine kinase receptor belonging to the TGF-β superfamily. It plays a critical role in regulating cellular processes such as proliferation, differentiation, and apoptosis by mediating signaling through BMP ligands. BMPR2 dysfunction, particularly mutations in the *BMPR2* gene, is strongly associated with heritable pulmonary arterial hypertension (HPAH), where over 70% of familial cases and ~20% of idiopathic cases exhibit genetic alterations. The receptor’s structure includes extracellular ligand-binding, transmembrane, and intracellular kinase domains, with mutations often disrupting downstream SMAD signaling or receptor trafficking.

BMPR2 antibodies are essential tools for studying receptor expression, localization, and signaling in both research and clinical contexts. They enable detection of BMPR2 in tissues (e.g., lung vasculature) via immunohistochemistry (IHC), Western blotting, or flow cytometry. Some antibodies target specific domains to distinguish functional receptor isoforms or mutant variants. In translational research, these antibodies help elucidate mechanisms of BMPR2 loss-of-function in PAH pathogenesis, including endothelial dysfunction and smooth muscle hyperplasia. Additionally, they are explored for diagnostic applications, such as quantifying BMPR2 levels in circulating cells, and therapeutic development, including antibody-based strategies to enhance BMPR2 signaling. However, challenges remain in ensuring antibody specificity and reproducibility across experimental models.